Rooting Out Health Care Fraud: Tales from the Front Line: A Health Policy and Bioethics Consortium
By some measures, as much as 5% of health care spending can be linked to fraud, and dangerous practices from for-profit medical product companies have led to widespread negative health outcomes. Health care providers and others directly involved in the health care marketplace are often in an optimal position to recognize problematic business practices. How do we optimize responsible whistleblowing and promote an ethical culture within science, medicine, and business?
Pieter Cohen, Associate Professor of Medicine, Cambridge Health Alliance and Harvard Medical School
Joan Gallagher, Former Sales Representative, InterMune
Register now online!
Learn more about the Health Policy and Bioethics Consortia.
The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations. They are organized by the Center for Bioethics at Harvard Medical School and the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.